Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Olaparib

OLAGLI

Hospices Civils de Lyon (OLAGLI) · Phase 2 · Completed · Enrollment 35

NCT03561870

ArmPopulationDoseEstimandComparatorEfficacy
Olaparib 300 mg BIDrecurrent IDH-mutant high-grade glioma (n = 35)300 mgSingle armn/r6-month PFS rate: 31.4%, primary endpoint, target 50% not metmedian PFS: 2.05 monthsmedian OS: 15.9 months